One of the most commonly used inhibitors of NF-κB pathway is bortezomib, a proteasome inhibitor developed for MM treatment based on the proteasome machinery which can inhibit NF-κB pathway activation. This evidence concerns the gene NFKB1 and Miyoshi myopathy.